RevenueNet IncomeP/EP/SEBITDividendStocksMarket capitalizationDebtLiabilitiesEquityAAQSEmployeesROEROAROCE
Societal CDMO Stock

Societal CDMO ROE 2024

Societal CDMO ROE

-0.23

Ticker

SCTL

ISIN

US75629F1093

WKN

A1XFAV

In 2024, Societal CDMO's return on equity (ROE) was -0.23, a -31.82% increase from the -0.33 ROE in the previous year.

Societal CDMO Aktienanalyse

What does Societal CDMO do?

Recro Pharma Inc. is a company operating in the biopharmaceutical industry, specializing in the development and marketing of innovative therapeutics. The company is based in Malvern, Pennsylvania, USA, and was founded in 2007. The history of Recro Pharma Inc. dates back to 1985, when the company was founded as ReceptoPharm. In 2008, it was renamed Recro Pharma Inc. to emphasize its focus on pharmaceutical activities. Since then, the company has made significant progress, including successful clinical trials and the introduction of innovative products. Recro Pharma follows a business model based on the development of therapeutics in the areas of pain management and anesthesia. The company aims to create solutions to alleviate pain in patients and improve their quality of life. Recro Pharma's goal is to bring high-quality products to the market that are distinguished by excellent safety, efficacy, and patient tolerance. Recro Pharma's product range currently includes two main areas. Firstly, the company has launched its medication Meloxicam for pain treatment in adults. Secondly, it has developed and distributes a portfolio of anesthesia-related therapeutics through its subsidiary Lumendi LLC. Meloxicam is a non-steroidal anti-inflammatory drug used for pain relief in adults. The medication is available in various forms such as tablets and capsules and is used in both hospital and outpatient care. Lumendi LLC specializes in the development and distribution of anesthesia-related therapeutics. The company's products include those for intubation and muscle relaxation in surgical procedures, as well as anesthesia for pain management. Lumendi's goal is to create innovative solutions to improve medical practice and shorten hospital stays. Recro Pharma Inc. aims to expand its product range through the development of further innovative solutions. The company continues to invest in research and development to develop new products and strengthen its position in the market. In 2020, Recro Pharma Inc. received FDA approval for the product IV Meloxicam. This is an intravenous form of the drug Meloxicam used for pain treatment in adults. This is a significant milestone for the company as it is now able to offer an alternative form of the medication. Recro Pharma Inc. has established itself as a significant player in the biopharmaceutical industry. The company aspires to further strengthen its position in the market and create innovative solutions to improve medical practice. With its high-quality products, Recro Pharma contributes to alleviating patients' pain and improving their quality of life. Societal CDMO ist eines der beliebtesten Unternehmen auf Eulerpool.com.

ROE Details

Decoding Societal CDMO's Return on Equity (ROE)

Societal CDMO's Return on Equity (ROE) is a fundamental metric evaluating the company's profitability relative to its equity. Calculated by dividing net income by shareholder's equity, ROE illustrates how effectively the company is generating profits from shareholders’ investments. A higher ROE represents enhanced efficiency and profitability.

Year-to-Year Comparison

Analyzing Societal CDMO's ROE on a yearly basis aids in tracking its profitability trends and financial performance. An increasing ROE suggests enhanced profitability and value generation for shareholders, whereas a declining ROE may indicate issues in profit generation or equity management.

Impact on Investments

Societal CDMO's ROE is instrumental for investors assessing the company's profitability, efficiency, and investment attractiveness. A robust ROE indicates the firm’s adeptness at converting equity investments into profits, thereby enhancing its appeal to potential and current investors.

Interpreting ROE Fluctuations

Changes in Societal CDMO’s ROE can emanate from variations in net income, equity capital, or both. These fluctuations are scrutinized to evaluate management’s effectiveness, financial strategies, and the inherent risks and opportunities, aiding investors in making informed decisions.

Frequently Asked Questions about Societal CDMO stock

What is the ROE (Return on Equity) of Societal CDMO this year?

The ROE of Societal CDMO this year is -0.23 undefined.

How has the Return on Equity (ROE) of Societal CDMO developed compared to the previous year?

The ROE of Societal CDMO has increased by -31.82% decreased compared to the previous year.

What impact does a high ROE (Return on Equity) have on investors of Societal CDMO?

A high ROE indicates that Societal CDMO generates good returns on capital and is successful in monetizing its investments. This is a positive indicator for investors.

What impact does a low ROE (Return on Equity) have on investors of Societal CDMO?

A low ROE can indicate that Societal CDMO is having difficulties monetizing its investments successfully and can be a negative signal for investors.

How does a change in the ROE (Return on Equity) of Societal CDMO affect the company?

A change in ROE (Return on Equity) of Societal CDMO can be an indicator of the financial performance of the company and demonstrate how successful the company is compared to other companies in the same industry.

How to calculate the ROE (Return on Equity) of Societal CDMO?

The ROE (Return on Equity) is calculated by dividing the company's profit by the total equity. The formula is: ROE = Profit / Total equity.

Which factors influence the ROE (Return on Equity) of Societal CDMO?

Some factors that can influence Societal CDMO's Return on Equity (ROE) include the efficiency in using equity, the profitability of the company, and the financing structure.

What strategic measures can take to improve the ROE (Return on Equity)?

To improve the Return on Equity (ROE), can take measures such as cost savings, increasing revenue, improving efficiency in the use of equity, and making changes in the financing structure. It is important for the company to conduct a thorough review of its financial situation to determine the best strategic actions to improve ROE.

How much dividend does Societal CDMO pay?

Over the past 12 months, Societal CDMO paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Societal CDMO is expected to pay a dividend of 0 USD.

What is the dividend yield of Societal CDMO?

The current dividend yield of Societal CDMO is .

When does Societal CDMO pay dividends?

Societal CDMO pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Societal CDMO?

Societal CDMO paid dividends every year for the past 0 years.

What is the dividend of Societal CDMO?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Societal CDMO located?

Societal CDMO is assigned to the 'Health' sector.

Wann musste ich die Aktien von Societal CDMO kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Societal CDMO from 8/10/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 8/10/2024.

When did Societal CDMO pay the last dividend?

The last dividend was paid out on 8/10/2024.

What was the dividend of Societal CDMO in the year 2023?

In the year 2023, Societal CDMO distributed 0 USD as dividends.

In which currency does Societal CDMO pay out the dividend?

The dividends of Societal CDMO are distributed in USD.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

Andere Kennzahlen von Societal CDMO

Our stock analysis for Societal CDMO Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Societal CDMO Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.